Data investigation

Is $99 Compounded Semaglutide Real? We Verified Every Provider at the Floor Price

Multiple telehealth providers advertise compounded semaglutide at $99 per month — well below the market median. We verified the licensing, pharmacy partner, dose, and total monthly cost for each one.

By the Weight Loss Rankings editorial team·9 min read·8 citations·Published 2026-04-06·Updated 2026-04-07
  • Pricing
  • Compounded GLP-1
  • Live dataset

The cheapest compounded semaglutide on the cash-pay telehealth market as of 2026-04-07 sits at $30 per month, advertised by one provider we track. That's only 15% of the market median of $199, and a small fraction of brand-name Wegovy cash-pay pricing. We verified each floor-price provider against our pricing index and pharmacy database to answer one question: is the floor price legitimate, or are there hidden gotchas?

Read this first: the regulatory landscape changed in 2025

The compounded semaglutide market in April 2026 is a very different animal from the 2023-2024 shortage-era market most older articles describe. Before you shop on price, you need to understand four things:

  1. The FDA declared the semaglutide shortage resolved on February 21, 2025. Semaglutide is no longer on the FDA Drug Shortages list. The Declaratory Order ended the regulatory discretion that let 503B outsourcing facilities mass-compound semaglutide during the shortage window.
  2. 503A compounding for individual patients is the only remaining legal pathway. A state-licensed 503A pharmacy can still compound semaglutide for a specific patient when a prescriber documents a patient-specific clinical need (e.g., an allergy to an excipient, a dose not commercially available). This is not the same as the bulk-compounding that dominated the market in 2024. Any provider still operating as though nothing changed is worth an extra round of diligence.
  3. Be extremely wary of “semaglutide sodium” or “semaglutide acetate.” FDA has issued repeated warnings that these salt forms are not the same API as FDA-approved semaglutide and have not been evaluated for safety or efficacy. Ask any prospective pharmacy to confirm in writing that they compound with base semaglutide, not a salt form.
  4. The market is contracting. Many of the large 503B outsourcing facilities that supplied telehealth platforms during the shortage have exited compounded semaglutide entirely. Pricing data on this page reflects the providers still actively offering it — that universe is smaller than it was a year ago, and availability may change without notice. Verify availability and legal status directly with any provider before signing up.

Sources: FDA Declaratory Order resolving the semaglutide shortage (Feb 21, 2025); FDA consumer alert on salt-form semaglutide; FDA 503A compounding guidance. Full citations in the References section below.

The market context: where $30 sits in the distribution

Across the 48 telehealth providers we track that offer compounded semaglutide, the price distribution looks like this:

StatisticMonthly price
Cheapest (floor)$30
10th percentile$99
Median$199
90th percentile$299
Most expensive$999

At $30, the floor price is 85% below the median provider and 90% below the 90th percentile. That kind of dispersion is unusual in any consumer drug market — it tells you the providers at the floor are playing a very different pricing game than the providers above it.

The provider at $30/month

Here's every provider we track that currently advertises compounded semaglutide at the $30/month floor, plus the editorial verification we've completed for each:

  • Lemonaid Health $30/month · WLR score 7.5/10 · ships to 50 states. Best for: budget-conscious shoppers.

The next tier: providers within $10 of the floor

As of this update, every provider above the floor sits at least $10/month higher — there's no second tier within striking distance.

What floor pricing actually buys you (and what it doesn't)

A $30/month advertised price almost always refers to the starting dose of compounded semaglutide (typically 0.25mg weekly), not the maintenance dose most patients end up at after titration (1.0mg or 1.7mg weekly). When you actually progress through your dose schedule, the monthly cost on most floor-priced providers rises to match the higher-dose tier on their pricing page. We track maintenance pricing on the same price tracker, and our 12-month price movement investigation documents how that floor has shifted over time.

Things the floor price does include for the verified providers above: a synchronous or asynchronous medical consultation, a prescription written by a licensed clinician, the compounded medication itself, basic patient support, and shipping. For a closer look at how the compounded vial actually compares to the brand-name pen on a day-to-day level, see our Wegovy pen vs compounded vial breakdown.

Things the floor price typically does not include: labs, insurance billing, syringes (some providers; check the per-provider page), expedited shipping, after-hours support, and dose changes that fall outside the manufacturer's standard titration. None of these are deal-breakers, but they're worth knowing about before you commit.

Red flags that mean the cheapest price is too good

Not every $30/month listing is legitimate. We verified that the providers above are licensed and shipping real product, but elsewhere on the open internet there are sub-floor offers that come with serious problems. Watch for:

  • No US-based prescriber. Compounded semaglutide requires a valid prescription from a clinician licensed in your state. Sites that skip the consultation step or that have a prescriber outside the US are violating federal law and your medication is not legitimate compounded product.
  • No named compounding pharmacy. Reputable providers name their fulfillment pharmacy on their website or in their consent forms. If you can't find out who is actually compounding your medication, that's a problem.
  • Salt forms. Multiple FDA warning letters cite providers using semaglutide sodium or semaglutide acetate (salt forms) instead of base semaglutide. Salt forms are not the same active ingredient as the molecule used in approved drugs and have not been evaluated for safety — our compounded semaglutide bioequivalence investigation walks through what “same molecule” actually means in this context. See our FDA warning letter investigation for the full pattern.
  • Prices below the legitimate floor. Anything dramatically cheaper than the $30/month tier documented here should be treated as suspicious until proven otherwise.

Methodology

Every price in this article is computed at render time from the Weight Loss Rankings provider dataset. When new providers are added or existing providers change their pricing, this article updates automatically — the prose adjusts to reflect the new floor, the new median, and any new verified providers tied at the floor.

The pricing dataset itself is verified directly against each provider's public website on a continuous basis by our editorial team. The verification process and data sources are documented at our methodology page. The full provider list and their pricing rows are available on the live price tracker.

Last data refresh: 2026-04-07.

References

  1. 1.U.S. Food and Drug Administration. FDA Declaratory Order: Resolution of the Semaglutide Injection Shortage (Feb 21, 2025). FDA Drug Shortages Database. 2025. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide+Injection&st=r
  2. 2.U.S. Food and Drug Administration. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss — consumer safety alert on salt forms (semaglutide sodium, semaglutide acetate). FDA.gov. 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
  3. 3.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers — 503A compounding pharmacy guidance. FDA.gov. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers